Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease [Yahoo! Finance]
Mirum Pharmaceuticals, Inc. - common stock (MIRM)
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Topline Phase 3 results expected in 2H 2026 FOSTER CITY, Calif., January 26, 2026 BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced the successful completion of its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases. With the completion of the acquisition, Mirum adds worldwide rights to brelovitug, a late-stage, fully human monoclonal antibody for chronic hepatitis delta virus (HDV), a rare and severe liver disease with no FDA-approved therapies in the United States. Brelovitug has received Breakthrough Therapy designation from the FDA and PRIME designation from the European Medicines Agency and is currently being evaluated in the global AZURE Phase 3 registrational program, with topline data expected in the second half of 2026. "With the acquisition now complete, our focus shifts to execution – adding the talented Bluejay team to Mirum as we complete the AZUR
Show less
Read more
Impact Snapshot
Event Time:
MIRM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIRM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIRM alerts
High impacting Mirum Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
MIRM
News
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille SyndromeBusiness Wire
- Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)Business Wire
- Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]Yahoo! Finance
- Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]Yahoo! Finance
- Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Morgan Stanley from $95.00 to $123.00. They now have an "overweight" rating on the stock.MarketBeat
MIRM
Earnings
- 11/4/25 - Beat
MIRM
Sec Filings
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- MIRM's page on the SEC website